All In Biotech

Drug Trial Radar · NCT06764628

A Study of SHR-4375 in Subjects With Solid Tumors

An Open-label, Single-arm, Multicenter Phase I/II Clinical Study of SHR-4375 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy

Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

208

Planned (sponsor's estimate)

Start

Jan 9, 2025

Primary completion

May 2027

Study completion May 2027

Sponsor

Sponsor type
Industry
First posted
Jan 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, three-part study to evaluate the safety and efficacy of SHR-4375 for injection in subjects with solid tumors.

Conditions

  • Solid Tumors

Interventions

  • SHR-4375Drug

    SHR-4375 injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: From Day 1 to 90 days after last dose.
  2. Dose limiting toxicity (DLT)Time frame: From Day 1 to 12 months.
  3. Maximal tolerable dose (MTD)Time frame: From Day 1 to 12 months.
  4. Recommended phase 2 dose (RP2D)Time frame: From Day 1 to 12 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.